Should I Buy IMNN? IMNN 2026 Analysis

Should You Buy Imunon Inc (IMNN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.220

1 Day change

52 Week Range

41.220

Analysis Updated At

2026/02/13

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Imunon Inc (IMNN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral to bearish, there are no significant trading trends or positive catalysts, and the company's financial performance shows declining net income and EPS. While the stock has potential for minor short-term gains, it does not align with the user's long-term investment goals.

Technical Analysis

The MACD is slightly positive but contracting, indicating weak momentum. The RSI is neutral at 44.736, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 3.301, with resistance at 3.526 and support at 3.076. Overall, the technical outlook is neutral to bearish.

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

Declining financial performance, including a 29.23% YoY drop in net income and a 76.94% YoY drop in EPS. No recent news or events to drive positive sentiment.

Financial Performance

In Q3 2025, the company reported zero revenue growth, a net income decline of -29.23% YoY to -$3,429,124, and a significant EPS drop of -76.94% YoY to -1.01. Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

1 Analyst Rating

Wall Street analysts forecast IMNN stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.220

Low

Averages

High

Current: 3.220

Low

Averages

High

D. Boral Capital

Jason Kolbert

Buy

Hold

downgrade

AI Analysis

2025-05-19

Reason

D. Boral Capital

Jason Kolbert

Price Target

AI Analysis

2025-05-19

downgrade

Buy

Hold

Reason

D. Boral Capital analyst Jason Kolbert downgraded Imunon to Hold from Buy without a price target. The company announced "encouraging" six-month follow-up data from its Phase 1 COVID-19 vaccine study, but the update is immaterial to the investment thesis, which remains centered on Imunon's ovarian cancer program, the analyst tells investors in a research note. The firm says the "more pressing development" is the recently filed prospectus for potentially dilutive financing that could create a significant number of new shares. Given the scale of dilution and uncertainty around shareholder approval, D. Boral downgraded the stock.

Boral Capital

D. Boral

Buy

downgrade

$29 -> $17

2025-05-13

Reason

Boral Capital

D. Boral

Price Target

$29 -> $17

2025-05-13

downgrade

Buy

Reason

D. Boral Capital lowered the firm's price target on Imunon to $17 from $29 and keeps a Buy rating on the shares. The firm now anticipates a series of dilutive financings that are likely to exceed its prior expectations. Imunon has entered a pivotal new phase in its development with the initiation of the Phase 3 OVATION 3 trial evaluating IMNN-001, its lead DNA-based immunotherapy candidate, in newly diagnosed advanced ovarian cancer, the analyst tells investors in a research note. With only $2.9M in cash as of March 31, the company's "financial position remains precarious," contends D. Boral.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMNN

Unlock Now

IMNN Should I Buy

IMNN Should I Buy

Should You Buy Imunon Inc (IMNN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch